secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001493152-26-007468
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MangoRx's new $99/mo injectable TRT sees 336% MoM sales growth, 54% CAC drop
----------------------------------------------------------------------------

- Month-over-month sales of injectable TRT program increased 336% since mid-December 2025 launch.
- Customer acquisition cost reduced by 54% over the same period.
- Global TRT market valued at $2.11-2.2B in 2025, expected CAGR 3.9% (TBRC report).
- CEO Jacob Cohen: TRT is key strategic focus; platform evolving to broader men's health.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315226007468/0001493152-26-007468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315226007468/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-007468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer